Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 6/2015

Open Access 01-05-2015 | Original Article

Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment

Authors: Johanna Svensson, Gertrud Berg, Bo Wängberg, Maria Larsson, Eva Forssell-Aronsson, Peter Bernhardt

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2015

Login to get access

Abstract

Purpose

Peptide receptor radionuclide therapy (PRRT) has become an important treatment option in the management of advanced neuroendocrine tumours. Long-lasting responses are reported for a majority of treated patients, with good tolerability and a favourable impact on quality of life. The treatment is usually limited by the cumulative absorbed dose to the kidneys, where the radiopharmaceutical is reabsorbed and retained, or by evident haematological toxicity. The aim of this study was to evaluate how renal function affects (1) absorbed dose to the kidneys, and (2) the development of haematological toxicity during PRRT treatment.

Methods

The study included 51 patients with an advanced neuroendocrine tumour who received 177Lu-DOTATATE treatment during 2006 – 2011 at Sahlgrenska University Hospital in Gothenburg. An average activity of 7.5 GBq (3.5 – 8.2 GBq) was given at intervals of 6 – 8 weeks on one to five occasions. Patient baseline characteristics according to renal and bone marrow function, tumour burden and medical history including prior treatment were recorded. Renal and bone marrow function were then monitored during treatment. Renal dosimetry was performed according to the conjugate view method, and the residence time for the radiopharmaceutical in the whole body was calculated.

Results

A significant correlation between inferior renal function before treatment and higher received renal absorbed dose per administered activity was found (p < 0.01). Patients with inferior renal function also experienced a higher grade of haematological toxicity during treatment (p = 0.01). The residence time of 177Lu in the whole body (range 0.89 – 3.0 days) was correlated with grade of haematological toxicity (p = 0.04) but not with renal absorbed dose (p = 0.53).

Conclusion

Patients with inferior renal function were exposed to higher renal absorbed dose per administered activity and developed a higher grade of haematological toxicity during 177Lu-DOTATATE treatment. The study confirms the tolerability of PRRT in patients with an advanced neuroendocrine tumour but indicates that patients with inferior renal function are at risk of being exposed to higher absorbed doses to normal tissue on treatment.
Literature
1.
Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78–88.CrossRefPubMed
2.
Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3] octreotate. J Nucl Med. 2011;52:1361–8.CrossRefPubMed
3.
Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136–43.CrossRefPubMed
4.
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.CrossRefPubMed
5.
Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47–51.CrossRefPubMed
6.
Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363–70.CrossRefPubMed
7.
Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D′Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Nucl Med Mol Imaging. 2011;55:205–21.
8.
Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.CrossRefPubMed
9.
Gupta SK, Singla S, Bal C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 2012;27:593–9.CrossRefPubMed
10.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.CrossRefPubMed
11.
Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Poppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.CrossRefPubMed
12.
Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.CrossRefPubMed
13.
Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S103–12.CrossRefPubMed
14.
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.CrossRefPubMed
15.
Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.CrossRefPubMed
16.
Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L, et al. Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med. 2013;27:74–7.CrossRefPubMed
17.
Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0),Tyr(3)-octreotate. J Nucl Med. 2005;46 Suppl 1:83S–91.PubMed
18.
19.
Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M, et al. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34:1368–72.CrossRefPubMed
20.
Larsson M, Bernhardt P, Svensson JB, Wangberg B, Ahlman H, Forssell-Aronsson E. Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. 2012;2:49.CrossRefPubMedCentralPubMed
21.
Fleming JS. A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol. 1979;24:176–80.CrossRefPubMed
22.
Eckerman K, Endo A. ICRP Publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP. 2008;38:7–96.CrossRefPubMed
23.
Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.PubMed
24.
Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.CrossRefPubMed
25.
He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, et al. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009;36:612–9.CrossRefPubMedCentralPubMed
26.
Grubb A, Christensson A. Time for new measurements in kidney disease diagnosis and follow-up. Lakartidningen. 2013;110:1021–4.PubMed
27.
Durand E, Chaumet-Riffaud P, Grenier N. Functional renal imaging: new trends in radiology and nuclear medicine. Semin Nucl Med. 2011;41:61–72.CrossRefPubMed
28.
Guerriero F, Ferrari ME, Botta F, Fioroni F, Grassi E, Versari A, et al. Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int. 2013;2013:935351.CrossRefPubMedCentralPubMed
29.
Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol. 2011;24:23–34.CrossRefPubMed
30.
Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897–904.CrossRefPubMed
31.
Garske U, Sandstrom M, Johansson S, Granberg D, Lundqvist H, Lubberink M, et al. Lessons on tumour response: imaging during therapy with (177)Lu-DOTA-octreotate. A case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma. Theranostics. 2012;2:459–71.CrossRefPubMedCentralPubMed
32.
Garske U, Sandstrom M, Johansson S, Sundin A, Granberg D, Eriksson B, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012;51:86–96.CrossRefPubMed
33.
Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)] octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.CrossRefPubMedCentralPubMed
34.
Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe(1)-Tyr(3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37:212–25. doi:10.​1007/​s00259-009-1216-8.CrossRefPubMed
Metadata
Title
Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment
Authors
Johanna Svensson
Gertrud Berg
Bo Wängberg
Maria Larsson
Eva Forssell-Aronsson
Peter Bernhardt
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3001-1

Other articles of this Issue 6/2015

European Journal of Nuclear Medicine and Molecular Imaging 6/2015 Go to the issue

Original Article

Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia

Editorial

Breast cancer: a new imaging approach as an addition to existing guidelines

Book Review

Torsten B. Moeller and Emil Reif (eds): Pocket Atlas of Sectional Anatomy, Computed Tomography and Magnetic Resonance Imaging, 4th edn. Vol. I: Head and Neck; Vol. II: Thorax, Heart, Abdomen and Pelvis

Letter to the Editor

Value of ventilation/perfusion SPECT for diagnosis of pulmonary embolism: response to comments by Sinzinger et al.

Original Article

Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up

Editorial Commentary

18F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma